Omeros Stock News

It's reverting to where it was before its massive uptick last week.

Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty.

Omeros Corporation (NASDAQ:OMER ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Offic

Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.

During the last session, Omeros Corporation (NASDAQ:OMER)’s traded shares were 0.47 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $6.10, reflecting an intraday loss of -5.72% or -$0.37. The 52-week high for the OMER share is $20.48, that puts it down -235.74 … How Could You Make A Quick Recovery From Omeros Corporation (NASDAQ: OMER) Given A -227.87% Drop From Highs? Read More »

Omeros press release (OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31.At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available…

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include

Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting.

Related Stocks: QTNT , RVAC , NSTD , NSTC , CLIM , GSQB , LYV , ENV , OMER , PSTH , CLVS , PCRX , GFLU , KKR , VIAC , HCVIU , ROLL , AQNU , KCGI.U , CFVI , VCXAU ,

Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.34 million during the last session, with the companys beta value hitting 0.63. At the close of trading, the stocks price was $6.32, to imply a decrease of -1.86% or -$0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -277.37% down since that peak Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next? Read More »

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In Endometrial Cancer Eisai Co.